Stock search

Ticker or company name

Incyte

INCY · NASDAQ · Biotechnology

$120,27Down −0,70 (−0,58%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$24,6 bn
Div. yield
—
Year to date
+22,5%
52 weeks: $89,25$132,60

Ratio score

44/100
Ratio would watch

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

3 ✓ · 2 — · 4 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM61,121,242,1
Forward P/E15,5—18,7
PEG4,2—4,1
P/S4,13,86,6
EV/EBITDA32,719,828,2
P/FCF12,8—26,0
P/B4,43,69,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 35 analysts

Buy
19
Hold
16
Sell
0

Beat the EPS forecast in 3 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 2026−3,93−3,60Up +8,3%
Q2 20262,143,09Up +44,1%
Q1 20261,401,81Up +29,4%
Q4 20251,971,80Down −8,5%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue1,56 bn1,67 bn1,27 bn1,51 bn1,37 bn1,22 bn1,05 bn1,18 bn1,14 bn1,04 bn881 m1,01 bn
EPS−3,862,811,471,462,112,040,800,950,54−2,040,750,89
Margin−50,4%35,0%23,8%19,9%31,1%33,3%15,0%17,1%9,4%−42,6%19,2%19,8%
FCF−675 m508 m369 m543 m559 m44,7 m266 m381 m311 m−576 m219 m148 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $65,8 m.

NameAmountSharesPrice
stein steven h6 Nov 2026 · sale$5,81 m48 576$119,66
stein steven h6 Nov 2026 · sale$8,81 m73 969$119,12
stein steven h6 Nov 2026 · sale$7,13 m60 270$118,27
stein steven h6 Nov 2026 · sale$2,62 m22 336$117,15
stein steven h6 Nov 2026 · sale$4,07 m35 042$116,06
tray thomas3 Nov 2026 · sale$72 566610$118,96
cagnoni pablo j15 Sep 2026 · sale$1,69 m13 985$120,49
cagnoni pablo j15 Sep 2026 · sale$1,11 m9 233$120,50
cagnoni pablo j19 Aug 2026 · sale$1,36 m10 801$125,56
cagnoni pablo j12 Aug 2026 · sale$1,30 m10 803$120,04
mayes patrick a5 Aug 2026 · sale$273 6462 207$123,99
cagnoni pablo j5 Aug 2026 · sale$1,31 m10 640$122,69
mayes patrick a3 Aug 2026 · sale$729 2046 055$120,43
mayes patrick a31 Jul 2026 · sale$273 8072 293$119,41
mayes patrick a31 Jul 2026 · sale$39 671326$121,69

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
6 Dec 1993

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
BIIBBiogen$251,6531would not consider107,8+2,3%3,4%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.